<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436978</url>
  </required_header>
  <id_info>
    <org_study_id>NL71116.100.20</org_study_id>
    <nct_id>NCT04436978</nct_id>
  </id_info>
  <brief_title>What is the Optimal Antithrombotic Strategy in Patients Presenting With Acute Coronary Syndrome Having Atrial Fibrillation With Indication for Anticoagulants?</brief_title>
  <acronym>WOEST 3</acronym>
  <official_title>What is the Optimal Antithrombotic Strategy in Patients Presenting With Acute Coronary Syndrome Having Atrial Fibrillation With Indication for Anticoagulants?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Patients with atrial fibrillation presenting with acute coronary syndrome have an indication
      for both oral anticoagulation and dual antiplatelet therapy (P2Y12 inhibitor plus low-dose
      aspirin). This triple therapy is, however, associated with increased bleeding risk. Several
      Randomized Controlled Trials have proven dual therapy omitting aspirin to reduce this
      bleeding risk compared to triple therapy without significant difference in efficacy (i.e.
      [cardiovascular-]death, stroke, recurrent myocardial infarction, stent thrombosis, and
      systemic embolism). However, none of these studies focussed on patients with acute coronary
      syndrome, who are at higher thrombotic risk than patients with stable coronary artery
      disease. Also, none of these studies were statistically powered for antithrombotic efficacy,
      withholding the practice guidelines to change their recommendations.

      Hypothesis:

      In patients with atrial fibrillation (and indication for oral anticoagulants) having acute
      coronary syndrome, dual therapy with oral anticoagulant + P2Y12 inhibitor is non-inferior for
      antithrombotic efficacy and superior for safety (i.e. bleeding) compared to triple therapy
      with oral anticoagulant + P2Y12 inhibitor + aspirin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thromboembolic complications</measure>
    <time_frame>1 year</time_frame>
    <description>Composite thrombotic end point of all-cause death, myocardial infarction, stent thrombosis, stroke, and systemic embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>1 year</time_frame>
    <description>Major or clinically relevant non-major bleeding as defined by the International Society of Thrombosis and Haemostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Landmark analysis of thromboembolic complications from 30 days</measure>
    <time_frame>30 days to 1 year</time_frame>
    <description>Landmark analysis of the primary thromboembolic endpoint (i.e. all-cause death, myocardial infarction, stent thrombosis, stroke, and systemic embolism) from 30 days after percutaneous coronary intervention (which is the minimum duration of triple therapy) to 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Landmark analysis of bleeding complications from 30 days</measure>
    <time_frame>30 days to 1 year</time_frame>
    <description>Landmark analysis of the primary bleeding endpoint (i.e. major or clinically relevant non-major bleeding as defined by the International Society of Thrombosis and Haemostasis) from 30 days after percutaneous coronary intervention (which is the minimum duration of triple therapy) to 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction and stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary revascularisation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life assessed by Short Form-12</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life assessed by EuroQol-5D-5L questionnaire</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Functional status for heart failure</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
    <description>Assessed by New York Heart Association grading for heart failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional status for angina pectoris</measure>
    <time_frame>30 days, 6 months, 12 months</time_frame>
    <description>Assessed by Canadian Cardiovascular Society grading for angina pectoris</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>NSTEMI - Non-ST Segment Elevation MI</condition>
  <condition>Bleeding</condition>
  <condition>Stroke</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Embolism</condition>
  <arm_group>
    <arm_group_label>Dual therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual therapy</intervention_name>
    <description>Oral anticoagulant + 1 year P2Y12 inhibitor</description>
    <arm_group_label>Dual therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple therapy</intervention_name>
    <description>Oral anticoagulant + 1 year P2Y12 inhibitor + 1-12 months low-dose aspirin</description>
    <arm_group_label>Triple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  Presenting with acute coronary syndrome with elevated cardiac markers (CK/CK-MB,
             troponin)

          -  Planned use of P2Y12 inhibitor

          -  History of or newly diagnosed (&lt;72 hours after presentation) atrial fibrillation or
             flutter with a long-term (≥ 1 year) indication for oral anticoagulants

        Exclusion Criteria:

          -  Conditions other than atrial fibrillation that require anticoagulation for which
             direct oral anticoagulants will not be sufficient (e.g. prosthetic mechanical heart
             valve, antiphospholipid syndrome)

          -  Contra-indications for intended direct oral anticoagulant, P2Y12 inhibitor, or aspirin

          -  History of known coagulopathy

          -  Severe bleeding in past 3 months (e.g. gastrointestinal, trauma, intracerebral)

          -  Estimated Glomerular Filtration Rate &lt; 15 mL/min/1.73m^2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurriën M ten Berg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Ziekenhuis Nieuwegein, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilbert Bor, MD</last_name>
    <phone>+31 (0)88 320 1241</phone>
    <email>w.bor@antoniusziekenhuis.nl</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>J.M. ten Berg</investigator_full_name>
    <investigator_title>Professor dr.</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Atrial Flutter</keyword>
  <keyword>STEMI - ST Elevation Myocardial Infarction</keyword>
  <keyword>NSTEMI - Non-ST Segment Elevation MI</keyword>
  <keyword>Oral Anticoagulant</keyword>
  <keyword>NOAC - Novel Oral Anticoagulant</keyword>
  <keyword>DOAC - Direct Oral Anticoagulant</keyword>
  <keyword>DAPT - Dual Antiplatelet Therapy</keyword>
  <keyword>Antithrombotic Therapy</keyword>
  <keyword>Dual Therapy</keyword>
  <keyword>Triple Therapy</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Stroke</keyword>
  <keyword>Stent Thrombosis</keyword>
  <keyword>Systemic Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

